Skip to main content

Victor José Gallardo Lopez

Institutions of which they are part

Research technician
Headache and Neurological Pain
Vall Hebron Institut de Recerca

Victor José Gallardo Lopez

Institutions of which they are part

Research technician
Headache and Neurological Pain
Vall Hebron Institut de Recerca

Projects

Assessing the role of glial cells in migraine and its chronification

IP: Marta Vila Pueyo
Collaborators: Laila Asskour, Victor José Gallardo Lopez
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 175000
Reference: PID2022-137287NA-I00
Duration: 01/09/2023 - 31/08/2026

Ministerio de Ciencia

Biomarcadores neuroinflamatorios en pacientes con migraña: prueba de concepto para el diagnóstico molecular de la enfermedad

IP: Marta Vila Pueyo
Collaborators: Laila Asskour, Patricia Pozo Rosich, Victor José Gallardo Lopez, Otilia Gliga
Funding agency: Fundación Eugenio Rodríguez Pascual
Funding: 24990
Reference: FERP-2023-MVP
Duration: 17/01/2024 - 16/01/2026

(PREDIMIGRAINE) Medicina de precisión para prevenir la cronificación de la migraña a través de la predicción de las crisis de dolor y de la respuesta al tratamiento con anticuerpos anti-CGRP utilizando estrategias multi-ómicas.

IP: Patricia Pozo Rosich
Collaborators: Alicia Alpuente Ruiz, Laila Asskour, Eulalia Gine Cipres, Victor José Gallardo Lopez, Edoardo Caronna
Funding agency: Instituto de Salud Carlos III
Funding: 369930
Reference: PMP22/00189
Duration: 01/01/2023 - 31/12/2025

BiOmarcadores Moleculares y clínicos de respuesta al tratamiento en los Ataques de Migraña (Estudio MAMBO).

IP: Marta Torres Ferrús
Collaborators: Alicia Alpuente Ruiz, Laila Asskour, Eulalia Gine Cipres, Victor José Gallardo Lopez, Edoardo Caronna, Laura Gómez Dabó
Funding agency: Instituto de Salud Carlos III
Funding: 75020
Reference: PI22/01530
Duration: 01/01/2023 - 31/12/2025

Related news

Two international studies led by Vall d'Hebron recommend early administration of specific drugs to prevent migraine to achieve a better response to therapy.

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

The study, conducted in more than 770 people, concludes that atogepant reduces the frequency of migraine attacks and the need to take medication.

Related professionals

Diego Yeste Fernandez

Diego Yeste Fernandez

Senior researcher
Growth and Development
Read more
Salima Lamrabti El Mourabit

Salima Lamrabti El Mourabit

Medium Grade Technician
Promotion Unit
Clinical Research Development Directorate
Read more
Joan Castell Conesa

Joan Castell Conesa

Molecular Medical Imaging
Read more
Daniel Perez Martinez

Daniel Perez Martinez

Predoctoral researcher
Diabetes and Metabolism
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.